The Brown Strain of

Sheng-Hsiung Huang, Hung-En Liao, Wen-Ping Jiang, Atsushi Inose, Wen-Liang Wu, Guan-Jhong Huang

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Gut microbiota-innate immune crosstalk in the initiation and progression of CRC: mechanisms and therapeutic potential.Frontiers in immunology · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sheng-Hsiung HuangDepartment of Healthcare Administration, Asia University, Taichung 413, Taiwan.

Hung-En LiaoDepartment of Healthcare Administration, Asia University, Taichung 413, Taiwan.ORCID 0000-0003-2840-6988

Wen-Ping JiangSchool of Pharmacy, China Medical University, Taichung 404, Taiwan.

Atsushi InoseFaculty of Pharmacy, Nihon Pharmaceutical University, Saitama 362-0806, Japan.ORCID 0009-0000-7846-8621

Wen-Liang WuSchool of Chinese Medicine, College of Chinese Medicine, China Medical University, Taichung 404, Taiwan.

Guan-Jhong HuangDepartment of Food Nutrition and Healthy Biotechnology, Asia University, Taichung 413, Taiwan.ORCID 0000-0002-9822-3485

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

5-Fluorouracil (5-FU) remains a cornerstone chemotherapeutic for colorectal cancer, exerting its antitumor effects primarily through disruption of DNA and RNA synthesis and subsequent induction of apoptosis. Nonetheless, its clinical efficacy is often compromised by prominent adverse effects, particularly mucositis. This study examines the potential of brown-strain

Indexed as

Epithelial-Mesenchymal TransitionFlammulinaFluorouracilInflammationOxidative StressTight JunctionsAnimalsAntimetabolites, AntineoplasticApoptosisIntestinal Barrier FunctionIntestinal MucosaMaleMiceMucositisAntimetabolites, AntineoplasticFluorouracil5-fluorouracilapoptosisbrown-strain Flammulina velutipesepithelial–mesenchymal transitioninflammationmucositisoxidative stressPI3K/AKT axistight junction

Identifiers

PMID41977395

DOI10.3390/ijms27073212

PMCPMC13073359

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.